語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Analysis file of drug-induced lung injury = expert opinion for analysis of big data /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Analysis file of drug-induced lung injury/ by Akihiko Gemma.
其他題名:
expert opinion for analysis of big data /
作者:
Gemma, Akihiko.
出版者:
Singapore :Springer Nature Singapore : : 2024.,
面頁冊數:
xii, 116 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:
Springer Nature eBook
標題:
Lungs - Wounds and injuries. -
電子資源:
https://doi.org/10.1007/978-981-97-3446-7
ISBN:
9789819734467
Analysis file of drug-induced lung injury = expert opinion for analysis of big data /
Gemma, Akihiko.
Analysis file of drug-induced lung injury
expert opinion for analysis of big data /[electronic resource] :by Akihiko Gemma. - Singapore :Springer Nature Singapore :2024. - xii, 116 p. :ill. (some col.), digital ;24 cm.
Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.)
This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.
ISBN: 9789819734467
Standard No.: 10.1007/978-981-97-3446-7doiSubjects--Topical Terms:
786009
Lungs
--Wounds and injuries.
LC Class. No.: RC756
Dewey Class. No.: 616.24
Analysis file of drug-induced lung injury = expert opinion for analysis of big data /
LDR
:02936nam a2200325 a 4500
001
1134328
003
DE-He213
005
20240802130230.0
006
m d
007
cr nn 008maaau
008
241213s2024 si s 0 eng d
020
$a
9789819734467
$q
(electronic bk.)
020
$a
9789819734450
$q
(paper)
024
7
$a
10.1007/978-981-97-3446-7
$2
doi
035
$a
978-981-97-3446-7
040
$a
GP
$c
GP
041
1
$a
eng
$h
jpn
050
4
$a
RC756
072
7
$a
MJL
$2
bicssc
072
7
$a
MED079000
$2
bisacsh
072
7
$a
MJL
$2
thema
082
0 4
$a
616.24
$2
23
090
$a
RC756
$b
.G323 2024
100
1
$a
Gemma, Akihiko.
$3
1455729
245
1 0
$a
Analysis file of drug-induced lung injury
$h
[electronic resource] :
$b
expert opinion for analysis of big data /
$c
by Akihiko Gemma.
260
$a
Singapore :
$c
2024.
$b
Springer Nature Singapore :
$b
Imprint: Springer,
300
$a
xii, 116 p. :
$b
ill. (some col.), digital ;
$c
24 cm.
505
0
$a
Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.)
520
$a
This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.
650
0
$a
Lungs
$x
Wounds and injuries.
$3
786009
650
0
$a
Lungs
$x
Diseases.
$3
769197
650
0
$a
Drugs
$x
Side effects.
$3
787558
650
1 4
$a
Pneumology.
$3
1387705
650
2 4
$a
Clinical Genetics.
$3
1394410
650
2 4
$a
Pathogenesis.
$3
1390667
650
2 4
$a
Oncology.
$3
593951
650
2 4
$a
Pharmacology.
$3
583819
650
2 4
$a
Genetics Research.
$3
1430011
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
856
4 0
$u
https://doi.org/10.1007/978-981-97-3446-7
950
$a
Medicine (SpringerNature-11650)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入